BBOT
NASDAQ · Biotechnology
Bridgebio Oncology Therapeut
$4.66
+0.00 (+0.00%)
Open$4.63
Previous Close$4.66
Day High$4.81
Day Low$4.60
52W High$14.87
52W Low$4.71
Volume—
Avg Volume919.0K
Market Cap382.43M
P/E Ratio—
EPS$-3.04
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+824.9% upside
Current
$4.66
$4.66
Target
$43.10
$43.10
$22.76
$43.10 avg
$48.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |
| Rev Growth | -2.3% | +22.3% | +7.3% |
| Debt/Equity | 0.31 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |